6.56

1.80% -0.12

Astria Therapeutics Inc (ATXS)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Astria Therapeutics Inc stock is traded at $6.56, with a volume of 100.28K. It is down -1.80% in the last 24 hours and up +13.89% over the past month. Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.

Previous Close:

$6.68

Open:

$6.68

24h Volume:

100.28K

Relative Volume:

0.22

Market Cap:

$370.21M

Revenue:

Net Income/Loss:

$-72.89M

P/E Ratio:

-2.7107

EPS:

-2.42

Net Cash Flow:

$-68.47M

1W Performance:

+5.13%

1M Performance:

+13.89%

6M Performance:

-11.47%

1Y Performance:

-42.81%

1-Day Range:

$6.48

$6.73

1-Week Range:

$5.9404

$6.73

52-Week Range:

$3.555

$12.92

Astria Therapeutics Inc Stock (ATXS) Company Profile

Name

Astria Therapeutics Inc

Sector

Healthcare (1161)

Industry

Biotechnology (651)

Phone

617-349-1971

Address

22 BOSTON WHARF ROAD, BOSTON

Employee

Twitter

Next Earnings Date

2025-03-11

Latest SEC Filings

ATXS's Discussions on Twitter

Compare ATXS with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ATXS Astria Therapeutics Inc	6.56	362.31M	0	-72.89M	-68.47M	-2.42
VRTX Vertex Pharmaceuticals Inc	472.27	120.73B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	564.64	61.80B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	328.00	42.46B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	591.74	35.22B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	296.46	31.99B	3.81B	-644.79M	-669.77M	-6.24

Astria Therapeutics Inc Stock (ATXS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-29-25	Initiated	Cantor Fitzgerald	Overweight
Jan-31-25	Initiated	JMP Securities	Mkt Outperform
Jul-29-24	Initiated	TD Cowen	Buy
Mar-28-23	Initiated	Evercore ISI	Outperform

Astria Therapeutics Inc Stock (ATXS) Latest News

03:38 AM

What analysts say about Astria Therapeutics Inc. stockFree Stock Market Forecast Reports - Autocar Professional

03:38 AM

Jul 23, 2025

What drives Astria Therapeutics Inc. stock priceConsistent double returns - Autocar Professional

Jul 23, 2025

Astria Therapeutics Inc. Stock Analysis and ForecastHigh-octane financial growth - jammulinksnews.com

Jul 23, 2025

Jul 22, 2025

Is Astria Therapeutics Inc. a good long term investmentFree Market Dynamics Reports - jammulinksnews.com

Jul 22, 2025

Jul 19, 2025

Published on: 2025-07-19 19:06:02 - jammulinksnews.com

Jul 19, 2025

Jul 18, 2025

Will Astria Therapeutics Inc. stock split in the near futureFree Stock Market Trend Analysis - Newser

Jul 18, 2025

Jul 16, 2025

why astria therapeutics inc. stock attracts strong analyst attentionPortfolio Boosting Stock Alerts - Newser

Jul 16, 2025

How Astria Therapeutics Inc. stock performs during market volatilityTechnical Breakout List - Newser

Jul 16, 2025

Why Astria Therapeutics Inc. stock attracts strong analyst attentionFree Professional Portfolio Management - beatles.ru

Jul 16, 2025

Jul 15, 2025

What makes Astria Therapeutics Inc. stock price move sharplyFree Access to Stock Community - beatles.ru

Jul 15, 2025

Astria: Betting On Navenibart In The Crowded HAE Arena - Seeking Alpha

Jul 15, 2025

Jul 09, 2025

Astria Therapeutics (ATXS) Soars 5.62% on Positive Trial Results - AInvest

Jul 09, 2025

Jul 08, 2025